Clinical trial
Docetaxel in Treating Patients With Recurrent or Refractory Germ Cell Cancer
NCT00002903 · European Organisation for Research and Treatment of Cancer - EORTC, Other · Completed
Key facts
| NCT number | NCT00002903 |
|---|---|
| Title | Docetaxel in Treating Patients With Recurrent or Refractory Germ Cell Cancer |
| Official title | PHASE II TRIAL WITH DOCETAXEL IN PATIENTS WITH RELAPSING GERM CELL CANCER |
| Lead sponsor | European Organisation for Research and Treatment of Cancer - EORTC, Other |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Extragonadal Germ Cell Tumor, Ovarian Cancer, Testicular Germ Cell Tumor |
| Intervention type | Drug |
| Interventions | docetaxel |
| Enrollment | 25 |
| Start date | Jul 1, 1995 |
| First posted | May 13, 2004 |
| Last update posted | Jul 2, 2012 |
| Countries | Austria, Belgium, Denmark, France, Germany, Greece, Israel, Italy, Netherlands, Norway, Portugal, Spain and 2 more |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: